Centre for Health Services Research

Dr Mark Nalder

PhD student
Centre for Health Services Research
Lecturer
Faculty of Medicine
View researcher profile
Mark Nalder

Publications

Journal Articles (2)
Conference Papers (5)

Journal Articles

White, Cassandra, Wardill, Hannah, Paul, Christine, Price, Timothy, Karapetis, Christos, Nalder, Mark, Burge, Matthew E., Thomas, Ann, Oldmeadow, Chris, Barker, Daniel, Edney, Laura C., Coller, Janet, Bowen, Joanne, Ostroff, Cheri, Cheek, Bruce, Carlson, Mel, Rankmore, Trumaine, Nagrial, Adnan, Clarke, Stephen, Chantrill, Lorraine, Ackland, Stephen and Scott, Rodney J. (2024). DPYD genotype-guided dose personalisation for fluoropyrimidine-based chemotherapy prescribing in solid organ cancer patients in Australia: GeneScreen 5-FU study protocol. BMC Cancer, 24 (1) 1369, 1-10. doi: 10.1186/s12885-024-13122-8
Kulasinghe, Arutha, Monkman, James, Nalder, Mark, O’Leary, Connor, Ladwa, Rahul and O’Byrne, Ken (2020). Transformation or progression from adenocarcinoma to small cell lung cancer detected by serially tracking mutations in the blood. Reports, 3 (4) 33, 33. doi: 10.3390/reports3040033

Conference Papers

Nalder, Mark, Kulasegaran, Tivya, Lundie, Ben, Woods, Rick, Eastgate, Melissa A., Wyld, David and Burge, Matthew E. (2024). Routine, prospective DPYD genotyping guided dose-individualisation for patients receiving fluoropyrimidines: Implementation, prevalence and patient safety outcomes from a multi-institutional clinical trial. 2024 ASCO Annual Meeting, Chicago, IL, United States, 31 May–4 June 2024. Alexandria, VA, United States: American Society of Clinical Oncology. doi: 10.1200/JCO.2024.42.16_suppl.12121
Kim, H. and Nalder, M. (2022). Surrogate Endpoints for Overall Survival in Cutaneous Squamous Cell Carcinoma: A Meta-Regression of Clinical Trials. ISPOR Europe 2022, Vienna, Austria, 6-9 November 2022. Amsterdam, Netherlands: Elsevier. doi: 10.1016/j.jval.2022.09.159
Kim, Hansoo, Kulasegaran, Tivya, Eastgate, Melissa, Wyld, David, Burge, Matthew and Nalder, Mark (2022). Cost-benefit of pre-treatment dihydropyrimidine dehydrogenase genotyping to individualise fluoropyrimidine-based chemotherapy in a contemporary Australian setting. HOBOKEN: WILEY.
Nalder, Mark, Ladwa, Rahul, Raina, Anant, Burge, Matthew E., Love, Amanda, Pattison, David A., Ramsay, Stuart and Wyld, David (2021). 177Lu-DOTATATE peptide receptor radionuclide therapy (PRRT) in patients with somatostatin-expressing neuroendocrine tumors: a real-world retrospective review of efficacy and safety from an Australian tertiary cancer Center. 2021 ASCO Annual Meeting I, Virtual, 4-8 June 2021. Alexandria, VA USA: American Society of Clinical Oncology. doi: 10.1200/jco.2021.39.15_suppl.e16198
Nalder, Mark and Chern, Boris (2019). Chemotherapy dosing practices in the obese population with solid organ malignancies: a single centre, retrospective audit. Medical Oncology Group of Australia Incorporated 40th Anniversary Annual Scientific Meeting, Leading the Way in Medical Oncology Education, Research and Clinical Practice, Canberra, ACT Australia, 14–16 August 2019. Chichester, West Sussex, United Kingdom: Wiley-Blackwell Publishing.